Jaipur, 3rd-6th December, 2009

Our Scientific Director, Dr. Gianluca Valentini, will take a spech at 41st Annual Conference of Society of Nuclear Medicine (India).

Acom Group

124I-βCIT is a new radiopharmaceutical compound for neurodegenerative disorder diagnosis with PET imaging. It is an analogue of cocaine and binds dopamine and serotonin transporters. Neurodegenerative disorders, such as Parkinson’s disease, are characterized by degeneration of dopaminergic neurons in the substantia nigra, with loss of their nerve terminals in the basal ganglia structure, especially in the striatum.

If you want try it in a clinical trial contact us by community. An interesting case report showed in reserved area, suggest a specific binding with melanoma brain metastasis.

If you want read it, please joint in to free Acom community

Acom Group

We’ll be at Barcelona EANM, where we’ll introduce our new web site. If you are at Congress, please visit us at our Stand (number 7) and you could enter directly in Community.

The most important innovation is Acom community . It would be a blog where exchange information and knowledge, new ideas and challenges between scientist and researcher about new isotopes and new radiopharmaceuticals, new technologies, and clinical trial outcomes.

Acom community would be a rendezvous for physicians, researchers, physicists and anyone who have an interest all around Nuclear Medicine. Otherwise visit web site and enter in Community.

Acom Group

ACOM partnership with INFN, Centro de Aplicationes Tecnologicas y Desarrollo Nuclear and Dipartimento di Fisica dell’Università di Padova led to an experimental applications:

Cyclotron-based neutron irradiation facility for BNCT experimental applications

C.Ceballos ¹², J. Esposito¹, E. Fagotti¹, P.Colautti¹, D. Moro¹³,

A. Pisent¹, P. Panichelli4, G. Valentini4.

1) INFN, Laboratori Nazionali di Legnaro, Viale dell’Università 2, I-35020 Legnaro, PD, Italy.

2) Centro de Aplicaciones Tecnlógicas y Desarrollo Nuclear, 5ta y 30, Miramar, Playa, Ciudad Habana, Cuba.

3) Dipartimento di fisica dell’Università di Padova, via Marzolo 8, I-35131 Padova, Italy

4) ACOM spa. Montecosaro Scalo, I-62010, MC, Italy.

A design of an irradiation facility to be used for Boron Neutron Capture Therapy (BNCT) experimental trials on cell cultures and small animals, using an accelerator-based neutron source is developed. The neutron converter is based on a cyclotron-produced deuteron beam (9 MeV, 40 µA) impinging on a beryllium target. The cyclotron considered here, is already used for the production of radioactive isotopes, devoted to medical applications. The design includes the deuteron beam transport line, the beryllium target, the neutron beam shaping assembly, and finally the irradiation room. The characterizations of the therapeutic beam and the dosimetric calculations outside the irradiation room have been performed by means of MCNPX transport code using in-air figure of merits. The study reveled that, even using a low power accelerator (0.36 kW), a thermal flux level of the order of 108 cm-2s-1, having a thermal-to-total neutron flux ratio of 0.92 is achieved.

Acom Group

It’s known that ¹⁸F-FCH is better than ¹⁸F- Floride in early detection of bone marrow metastases. This evidences, also published in Eur J Nucl Med Mol Imaging (2008) 35:1766-1774 will change clinical management of patients.

We have required to the relevant regulatory Competent Authority the authorisation for a phase three clinical trial to accurately detect early bone metastases in case of prostate cancer, that might not be detected using conventional available methods.

Would you like to be an investigator of this clinical trial? What about this in your experience? Contact us for any questions, ideas or doubt in regard to this argument.

Acom Group